Two Omega-3s, Two Roles
EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are marine-based long-chain omega-3 fatty acids found in fish oil and algae oil. Though they are often mentioned together, they have distinct biological roles in the body.
Modern research has begun clarifying when one matters more than the other.
EPA: The Anti-Inflammatory Specialist
EPA (a 20-carbon fatty acid) primarily functions in regulating inflammatory processes.
EPA's Key Functions
- Eicosanoid precursor: EPA is the substrate for synthesising anti-inflammatory eicosanoids (prostaglandins, thromboxanes, leukotrienes)
- Resolvin source: E-series resolvins derive from EPA, helping to "switch off" inflammation
- Competes with arachidonic acid: EPA competes with arachidonic acid (omega-6) for the same enzymes, thereby reducing the production of pro-inflammatory compounds
EPA and Heart Health: The REDUCE-IT Trial
The REDUCE-IT trial (Bhatt et al. 2019) was remarkable:
- Used pure EPA (icosapent ethyl, 4 g/day)
- 25% lower risk of major cardiovascular events
- This was the first trial using EPA alone (not an EPA+DHA combination)
- Results were substantially stronger than earlier EPA+DHA studies
This raised the question: is EPA more important for heart health than DHA?
DHA: The Building Block of Brain and Vision
DHA (a 22-carbon fatty acid) is a structural component forming a significant part of certain tissues.
DHA's Key Functions
- Brain tissue: DHA makes up ~40% of the brain's polyunsaturated fatty acids
- Retina: DHA makes up ~60% of the retina's photoreceptor fatty acids
- Cell membranes: DHA influences membrane fluidity and receptor function
- Foetal development: DHA accumulates rapidly in the foetal brain during the third trimester
DHA and EFSA-Approved Claims
EFSA has approved DHA-specific claims:
- "DHA contributes to the maintenance of normal brain function" — 250 mg DHA per day
- "DHA contributes to the maintenance of normal vision" — 250 mg DHA per day
- "DHA contributes to the normal brain development of the foetus and breastfed infants" — maternal DHA intake of 200 mg per day in addition to the EPA+DHA recommendation
EPA vs DHA: Comparison Table
| Property | EPA | DHA |
|---|---|---|
| Carbon chain length | 20 carbons | 22 carbons |
| Double bonds | 5 | 6 |
| Primary role | Inflammation regulation | Structural component |
| Heart health | Stronger evidence (REDUCE-IT) | Part of overall omega-3 benefit |
| Brain function | Less evidence | Primary structural fatty acid |
| Vision | Less important | Critically important |
| Pregnancy | Important | Critically important |
| Inflammation | Primary role | Supporting role |
| EFSA-specific claim | No (only combined with DHA) | Yes (brain, vision, foetal development) |
Calder (2017): EPA's Anti-Inflammatory Role
Professor Philip Calder published a comprehensive review of EPA's and DHA's anti-inflammatory properties:
Key conclusions:
- EPA is a more potent anti-inflammatory than DHA
- EPA directly competes with arachidonic acid (omega-6)
- DHA also has anti-inflammatory properties, but through a different mechanism
- Both are needed for optimal health
What Is the Best Ratio?
Typical fish oil has an 18:12 (EPA:DHA) ratio, approximately 3:2.
But the optimal ratio depends on your goal:
Heart health: Higher-EPA product (2:1 or 3:1 EPA:DHA)
Brain and cognitive health: Higher-DHA product (1:2 EPA:DHA or pure DHA)
Pregnancy: DHA-rich product (at least 200 mg DHA per day in addition to EPA+DHA)
General health: Balanced ratio (2:1 or 3:2 EPA:DHA)
Practical Summary
EPA and DHA are both important omega-3 fatty acids, but they serve different biological functions:
- For heart health — focus on EPA
- For brain health — focus on DHA
- For pregnancy — DHA is critically important
- For general health — a balanced EPA+DHA combination
For the EFSA-approved claim (normal heart function), at least 250 mg of EPA and DHA per day is required.
---
Read more:
References
- Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., Tardif, J. C., & Ballantyne, C. M. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine, 380(1), 11–22.
- Calder, P. C. (2017). Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochemical Society Transactions, 45(5), 1105–1115.
- Mozaffarian, D., & Wu, J. H. (2011). Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. Journal of the American College of Cardiology, 58(20), 2047–2067.
- Swanson, D., Block, R., & Mousa, S. A. (2012). Omega-3 fatty acids EPA and DHA: health benefits throughout life. Advances in Nutrition, 3(1), 1–7.
Disclaimer
Dietary supplements are not a substitute for a varied, balanced diet and healthy lifestyle.
